Seminar on Art of Cancer Care and Its Clinical Translation in China

04 Dec 2026 10.00 AM - 11.00 AM LHN-TR+18 (The Arc, LHN-L1-06) Current Students, Public

Dr Zhang Jun

Professor and Chief Physician in the Department of Oncology, Ruijin Hospital

Shanghai Jiao Tong University School of Medicine, China

This seminar will be chaired by A/P Huang Changjin.

Seminar Abstract

Against substantial cancer burden pressure in China with ongoing cancer spectrum transition, the Chinese Anti Cancer Association (CACA) advances full cycle cancer governance spanning prevention, screening, diagnosis, treatment, rehabilitation and survivorship, and promotes standardized whole journey supportive care practice. Clinical translational bottlenecks remain a key unmet challenge. Anchored by the Mechanism Empowered Ruijin Cancer Incubator (MERCI), Committee of Neoplastic Supportive-care (CONS) and Ruijin Oncology Alliance advocates physician scientists as innovation chain stewards and establishes three core pillars: biological cognition, precision therapeutic decision making, and precision response evaluation. Centered on biology oriented clinical decision making, our group addresses critical scientific challenges including organ specific metastatic tropism and adaptive tumour evolution under therapeutic pressure. Translational outputs include biomarker guided systemic therapy stratification and our jointly developed OX40 agonist, whose phase I data received an oral presentation at the 2026 World Cancer Congress. This mechanism driven, patient centered paradigm delivers actionable real world insights for China’s evolving oncology landscape.

Speaker's Biography 
Dr. Zhang Jun is Professor and Chief Physician in the Department of Oncology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China. His clinical and research interests focus on gastrointestinal cancers, particularly the molecular mechanisms of gastric cancer metastasis, treatment resistance, and targeted and anti-angiogenic therapies. He received his medical and doctoral training at Shanghai Second Medical University and Shanghai Jiao Tong University School of Medicine, and undertook visiting research at The University of Texas MD Anderson Cancer Center. He has led multiple National Natural Science Foundation of China projects and previously served as a Programme Director in its Department of Health Sciences. Dr. Zhang also holds leadership roles in national oncology societies, including Chair of the Committee of Neoplastic Supportive Care of the China Anti-Cancer Association and Vice-Chair of the Anti-Angiogenesis Committee of the Chinese Society of Clinical Oncology.